Pacira BioSciences Stock Forecast, Price & News

12 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Pacira BioSciences in the last twelve months. There are currently 4 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Pacira BioSciences stock.
View analyst ratings for Pacira BioSciences or view top-rated stocks.

Wall Street analysts have given Pacira BioSciences a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Pacira BioSciences wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Pacira BioSciences is scheduled to release its next quarterly earnings announcement on Thursday, May 6th 2021.
View our earnings forecast for Pacira BioSciences.

Pacira BioSciences, Inc. (NASDAQ:PCRX) announced its earnings results on Wednesday, February, 24th. The company reported $0.87 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $0.81 by $0.06. The business earned $130.90 million during the quarter, compared to analysts' expectations of $130.91 million. Pacira BioSciences had a trailing twelve-month return on equity of 10.71% and a net margin of 29.95%. Pacira BioSciences's revenue for the quarter was up 6.9% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.56 EPS.
View Pacira BioSciences' earnings history.

Pacira BioSciences' stock was trading at $35.19 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, PCRX stock has increased by 78.0% and is now trading at $62.65.
View which stocks have been most impacted by COVID-19.

12 brokers have issued 1-year target prices for Pacira BioSciences' shares. Their forecasts range from $48.00 to $94.00. On average, they expect Pacira BioSciences' stock price to reach $77.50 in the next year. This suggests a possible upside of 23.7% from the stock's current price.
View analysts' price targets for Pacira BioSciences or view top-rated stocks among Wall Street analysts.

54 employees have rated Pacira BioSciences CEO Dave Stack on Glassdoor.com. Dave Stack has an approval rating of 45% among Pacira BioSciences' employees. This puts Dave Stack in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Pacira BioSciences include Johnson & Johnson (JNJ), Pfizer (PFE), Merck & Co., Inc. (MRK), AbbVie (ABBV), Eli Lilly and (LLY), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Royalty Pharma (RPRX), Horizon Therapeutics Public (HZNP), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), Nektar Therapeutics (NKTR), Corcept Therapeutics (CORT), Supernus Pharmaceuticals (SUPN) and Endo International (ENDP).
View all of PCRX's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Pacira BioSciences investors own include Gilead Sciences (GILD), NVIDIA (NVDA), Micron Technology (MU), ACADIA Pharmaceuticals (ACAD), Skyworks Solutions (SWKS), AbbVie (ABBV), Pfizer (PFE), QUALCOMM (QCOM), Exelixis (EXEL) and Tesla (TSLA).

Pacira BioSciences trades on the NASDAQ under the ticker symbol "PCRX."

Pacira BioSciences' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Tributary Capital Management LLC (0.27%), Scout Investments Inc. (0.26%), Hodges Capital Management Inc. (0.17%), State of Alaska Department of Revenue (0.07%), Capital Insight Partners LLC (0.05%) and Toth Financial Advisory Corp (0.04%). Company insiders that own Pacira BioSciences stock include Andreas Wicki, Charles A Reinhart III, Charles Anthony Laranjeira, David M Stack, Dennis Mcloughlin, John P Phd Longenecker, Kristen Marie Williams, Laura Brege, Lauren Bullaro Riker, Max Reinhardt, Paul J Hastings, Richard Scranton and Roy Winston.
View institutional ownership trends for Pacira BioSciences.

PCRX stock was sold by a variety of institutional investors in the last quarter, including Tributary Capital Management LLC, State of Alaska Department of Revenue, Veriti Management LLC, and NEXT Financial Group Inc. Company insiders that have sold Pacira BioSciences company stock in the last year include Andreas Wicki, Charles A Reinhart III, Charles Anthony Laranjeira, David M Stack, Kristen Marie Williams, Laura Brege, Lauren Bullaro Riker, Max Reinhardt, Paul J Hastings, and Roy Winston.
View insider buying and selling activity for Pacira BioSciences or view top insider-selling stocks.

PCRX stock was bought by a variety of institutional investors in the last quarter, including Scout Investments Inc., Hodges Capital Management Inc., Capital Insight Partners LLC, Campbell Newman Asset Management Inc., Everence Capital Management Inc., Loring Wolcott & Coolidge Fiduciary Advisors LLP MA, Toth Financial Advisory Corp, and Rothschild Investment Corp IL.
View insider buying and selling activity for Pacira BioSciences or or view top insider-buying stocks.

Shares of PCRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of PCRX stock can currently be purchased for approximately $62.65.

Pacira BioSciences has a market capitalization of $2.75 billion and generates $421.03 million in revenue each year. The company earns $-11,020,000.00 in net income (profit) each year or $0.86 on an earnings per share basis.

Pacira BioSciences employs 624 workers across the globe.

The official website for Pacira BioSciences is www.pacira.com.

Pacira BioSciences is headquartered at 5 SYLVAN WAY SUITE 300, PARSIPPANY NJ, 07054.

Pacira BioSciences' mailing address is 5 SYLVAN WAY SUITE 300, PARSIPPANY NJ, 07054. The company can be reached via phone at 973-254-3560 or via email at [email protected]